RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Retained earnings

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndRetained earnings (Million USD)YoY (%)
Dec 31, 2024-7,288+3.97%
Dec 31, 2023-7,010+6.70%
Dec 31, 2022-6,569+20.80%
Dec 31, 2021-5,438+18.60%
Dec 31, 2020-4,585+23.03%
Dec 31, 2019-3,727+31.19%
Dec 31, 2018-2,841+32.28%
Dec 31, 2017-2,148+29.63%
Dec 31, 2016-1,657+32.90%
Dec 31, 2015-1,247+30.32%
Dec 31, 2014-957+60.45%
Dec 31, 2013-596+17.60%
Dec 31, 2012-507+26.44%
Dec 31, 2011-401+16.79%
Dec 31, 2010-343

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)